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Background and Objectives: Laparoscopic surgical
techniques in pregnancy have been accepted and pose
minimal risks to the patient and fetus. We present the first
reported case of a pregnant woman with immune throm-
bocytopenia purpura who underwent laparoscopic
splenectomy during the second trimester.
Methods and Results: The anesthesia, hematology, and
obstetrics services closely followed the patient’s preoper-
ative and intraoperative courses. After receiving immu-
nization, stress dose steroids, and prophylactic antibi-
otics, she underwent a successful laparoscopic splenec-
tomy. After a short hospital stay, the patient was dis-
charged home.
Conclusion: Immune thrombocytopenia purpura can be
an indication for splenectomy. As demonstrated in
appendectomy, cholecystectomy, and our case presenta-
tion, laparoscopic splenectomy can be safely performed
during pregnancy.
Key Words: Thrombocytopenia, Laparoscopy, Splenect-
omy, Pregnancy.
INTRODUCTION
Since the advent of laparoscopic surgery in the early
1980s, multiple applications for it have been found in
almost all surgical specialties. Laparoscopic procedures
in pregnancy are becoming accepted as clinicians gain
more experience. Minimally invasive management of
appendicitis and acute cholecystitis has been accepted as
safe in the pregnant patient and is supported by several
case reports and studies. Other procedures will likely be
added to this armamentarium.
Immune thrombocytopenic purpura (ITP) is an autoim-
mune disorder in which IgG autoantibodies bind to the
platelet membrane.1 This causes premature clearance of
platelets by macrophages in the spleen and other organs
of the reticulo-endothelial system. The spleen is believed
also to be a major source of autoantibody production in
this disorder. ITP may be acute or chronic: the chronic
form is more common in adult patients. The female to
male ratio is 2:1. Women with this anomaly range in age
from 20 to 40 years. Thus, ITP often complicates preg-
nancy, although pregnancy per se is not believed to
induce ITP or alter the disease course. These IgG anti-
bodies are actively transported across the placenta mak-
ing diagnosis during pregnancy critical. Prednisone con-
stitutes a very effective first-line treatment in most
patients with ITP, but only about 25% of patients main-
tain acceptable platelet counts when steroids are tapered
off or withdrawn. For the majority of those who fail cor-
ticosteroids, splenectomy is very effective in inducing a
remission with 70 to 80% of patients with ITP respond-
ing either to corticosteroids or splenectomy.1
MATERIALS AND METHODS
The patient is a 21-year-old Hispanic female, gravida 2,
para 1, in her 23rd week of pregnancy. During her first
prenatal visit at 11 weeks gestation, a routine laboratory
examination revealed a platelet count of 12,000. She
denied previous bleeding complications with her first
pregnancy, but she had not sought prenatal care for lab-
oratory assessment at that time. During this, her second
pregnancy, the patient sought medical care and reported
gum bleeding when she brushed her teeth and easy
bruising. She was evaluated in the Hematology Clinic
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within the week and found to have a platelet count of
2,000/mL.  Due to this extremely low platelet count, the
patient was admitted to the hospital. She was considered
to have ITP on the basis of her history, the absence of
abnormal physical findings, and an isolated thrombocy-
topenia with otherwise normal hematological parameters
and blood smear. The results of the analysis of other rel-
evant hematologic parameters were: negative antinuclear
antibody, negative human immunodeficiency virus (HIV)
antibody, and normal prothrombin time and partial
thromboplastin time. Liver synthetic function and
transaminases were normal, as was renal function, based
on blood chemistry. A bone marrow biopsy was not per-
formed, in keeping with the American Society of
Hematology guidelines.2
Prednisone therapy at 2 mg/kg was initiated, and the
platelet count rose quickly reaching a maximum of
60,000/mL. As the steroid therapy was tapered from 60
mg twice a day (BID) at discharge to 20 mg BID over a
3-week period, the platelet counts dropped, and the
patient developed bruising and had a platelet count of
30,000/mL. We increased the prednisone to 40 mg BID.
The patient was very bothered by the Cushingoid effects
of the corticosteroids. On one occasion, she stopped her
steroid therapy abruptly. She came to the clinic and was
found to have a platelet count of 30,000/mL. In addition
to our concern about her lack of compliance, we were
also concerned with the steroid’s late effects, including
pregnancy-induced hypertension, especially in light of
the relatively high doses needed to keep her platelet
count at a safe and asymptomatic level. We considered
giving her intravenous gamma globulin therapy, but it
requires a compliant patient for laboratory follow-up and
repeat dosing.
We considered this a treatment failure and therefore dis-
cussed possible surgical approaches. Ultrasound at 20
weeks demonstrated a healthy fetus. After consultation
between the perinatologists and hematologists involved
in this case, we offered splenectomy as an alternative
therapy. We discussed the risks and benefits of splenec-
tomy in the second trimester with the patient who elect-
ed to undergo the laparoscopic splenectomy.
Approximately 2 weeks before the procedure, the patient
was given pneumococcal, meningococcal, and hemo-
philus influenzae vaccines in preparation for the splenec-
tomy. Her prednisone dose was also increased to 40 mg
BID to obtain a higher platelet count for the surgical pro-
cedure. She was typed and crossed for 2 units of packed
red cells. Bolus intravenous steroids of 100 mg every 6
hours were given to provide stress-dose therapy. The
platelet count was 158,000/mL at the time of splenecto-
my. Prophylactic antibiotics were also administered.
Sequential or intermittent compression devices were also
used to prevent deep venous thrombosis.
In the operating room, the patient was placed in the left
lateral position during induction keeping the uterus off
the vena cava. A fetal heart rate of 144 beats/minute was
measured prior to surgery. Aggressive hydration was
given to prevent hemodynamic changes associated with
pneumoperitoneum. The patient was then placed in the
right lateral position. The operating table was broken to
open the distance between the costal margin and the
iliac crest. The Hasson cannula was placed under direct
visualization (Figure 1).3 Insufflation was kept below 14
mm Hg and the end-tidal CO2 was monitored continu-
ously during the procedure. The remaining ports were
placed as indicated (Figure 1),3 using 12-mm ports so
that the stapling device [Endo Vascular GIA (USSC,
Norwalk, CT)] could be best positioned.
Dissection began with the splenocolic ligament. Traction
on the splenic flexure of the colon was maintained using
a laparoscopic Babcock while shears with monopolar
cautery were used to divide the attachments. The ultra-
sonic coagulator was used to divide the splenorenal and
splenophrenic attachments. The spleen was lifted and
rotated using a closed Babcock. The lesser sac was
entered as the gastrosplenic ligament, and short gastric
vessels were taken with the ultrasonic coagulator. Careful
Figure 1. ITP: Laparoscopic treatment.spreading with a blunt dissector exposed the hilar ves-
sels, which were divided with the vascular stapler [Endo
Vascular GIA (USSC, Norwalk, CT)]. Three applications of
the device were used. The 6” x 8” entrapment sac was
then placed through a port site. The staple line at the
splenic hilum was grasped to deposit the spleen in the
sac. The spleen was morsellated in the sac with a ring
forcep prior to removal through a port site. The splenic
vessels were inspected and the operative site irrigated
before removing all ports under direct visualization.
Accessory splenic tissue was not visualized. The fascia
was closed under laparoscopic guidance.
RESULTS
No operative or obstetric complications occurred. Blood
loss was less than 100 cc. The patient received 3 L of
crystalloid and made 1300 cc of urine. Systolic blood
pressure was maintained in the range of 105 to 125 mm
Hg. End-tidal CO2 measurements ranged from 30 to 35
(units). The operative time was 4 hours and 20 minutes.
A fetal heart rate of 150 beats/minute was noted in the
recovery room. On postoperative day 1, the platelet
count was 213,000/mL. Sequential compression devices
were continued, as venous thrombosis is a concern with
extremely elevated platelet counts that can occur after
splenectomy. A maximum level of 600,000/mL was
reached on postoperative day 9 that subsequently fell to
the normal range. A normal platelet count was main-
tained through the remainder of her pregnancy. The
patient was discharged home on an oral pain medication
and a steroid taper. The pregnancy resulted in a term
infant delivered vaginally without bleeding complica-
tions. At the time of delivery, the maternal platelet count
was 357,000/mL, and the baby’s platelet count was
310,000/mL. Approximately 1 year after splenectomy, a
small port site hernia was repaired, primarily on an out-
patient basis. The patient’s platelet count at that time was
345,000/mL.
DISCUSSION
Isolated thrombocytopenia during pregnancy can have
diverse causes. An asymptomatic reduction in platelet
counts, between 90,000/mL and 150,000/mL, is usually
considered “gestational” thrombocytopenia and of no
clinical significance.4 Lower platelet counts suggest ITP.
Other causes include HIV-associated thrombocytopenia,
lupus, malignancy and microangiopathic hemolytic
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processes. Appropriate laboratory tests ruled out the for-
mer anomalies in this patient; neither clinical nor labora-
tory evidence of malignancy or HEELP syndrome
(HEmolysis, Elevated Liver function, Low Platelets) exist-
ed.
Immunoglobulin therapy is considered safe in the preg-
nant patient but is extremely costly and requires a com-
pliant patient. The initial treatment costs approximately
$10,000 with maintenance treatments costing $2,500 to
$5,000. At the time of presentation, immunoglobulin was
in a severe shortage. Steroid therapy can worsen gesta-
tional diabetes, predispose the patient to infection, and
complicate pregnancy-induced hypertension. Both regi-
mens are considered safe for the fetus. Immunoglobulin
G crosses the placenta in increasing amounts as gestation
increases and may benefit the fetus at delivery.5
Cytotoxic agents such as azathioprine or cyclophos-
phamide are assumed to be teratogenic.2 Because the
maternal IgG antibodies are transported across the pla-
centa, the fetus can become thrombocytopenic. Maternal
platelet counts and response to treatment do not reliably
predict fetal platelet counts. The concern then is for fetal
injury during delivery, namely intracerebral hemorrhage.
In a review of the literature concerning pregnant women
with ITP, the incidence of infant platelet counts less than
50,000/mL is between 6% and 70%, but severe thrombo-
cytopenia less than 20,000/mL is 7%.6,7
A treatment strategy for gravidas with ITP is difficult to
formulate. If the mother is asymptomatic and the fetal
platelet count is normal, no therapy would be indicated.
However, the fetal platelet count is difficult to predict. It
cannot be determined without invasive sampling that
carries the risks of fetal distress, bradycardia, and even
death.2 Additionally, maternal steroid therapy does not
prevent fetal thrombocytopenia.7 A panel of hematolo-
gists from the American Society of Hematologists in 1996
could not reach a consensus as to a treatment plan. They
were less likely to recommend splenectomy due to per-
ceived maternal and fetal risks.2 Our case presentation
presents laparoscopic splenectomy, an alternative with
the added benefits of less need for narcotics, earlier
return to activity, and the avoidance of uterine manipu-
lation.
Several physiological differences exist in the pregnant
patient that must be considered before proceeding with
any surgical procedure. In regard to hemodynamics, sys-
temic vascular resistance in pregnancy is decreased by 2Immune Thrombocytopenic Purpura During Pregnancy: Laparoscopic Treatment, Anglin BV et al.
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mechanisms. Progesterone exerts direct smooth muscle
relaxation in both the vascular tree and the gastrointesti-
nal tract. The second mechanism is prostacycline pro-
duction, which causes desensitization of the vascular
beds to catecholamines.8 This is important with induction
and abdominal insufflation. The patient must be well
hydrated and positioned so that the uterus does not com-
promise cardiac return.
A second important consideration is the acid-base regu-
lation during pregnancy. The patient maintains a com-
pensated respiratory alkalosis due to increased tidal vol-
umes and respiratory rates. The kidneys compensate by
excreting bicarbonate.8 The gravid patient is therefore
more susceptible to acidosis as is the fetus. Again, ade-
quate hydration and proper positioning are important.
Carbon dioxide absorption during pneumoperitoneum is
also an issue. Hunter et al9 studied the effects of carbon
dioxide pneumoperitoneum in pregnant sheep. They
found that the pH of both the ewe and the fetus
decreased. However, respiratory compensation occurred
in 30 minutes. After desufflation, all parameters returned
to normal. The conclusion from this study is that pneu-
moperitoneum does not place the fetus at significant risk.
Similar results were found in other animal studies.10
Laparoscopy during pregnancy has been found to be as
safe as open surgery. A Swedish study11 showed that no
difference occurs in fetal demise and fetal malformations
between patients undergoing laparoscopy or laparotomy.
Another issue is that the pregnant patient is in a hyper-
coagulable state due to the increased production of clot-
ting factors. A 20% increase occurs on average in fibrino-
gen levels.8 Perioperatively, these patients therefore need
prophylactic measures such as sequential compression
devices or low-dose heparin therapy. A benefit of laparo-
scopic procedures in general is the earlier return to activ-
ity avoiding prolonged bedrest and the inherent possible
complications.
Benefits of Laparoscopic Surgery
Patients undergoing laparoscopic procedures often use
less pain medication.12 This is important due to the dele-
terious effects that chronic narcotic use can have on the
fetus. Chronic narcotic use has been associated with pre-
mature labor and fetal growth retardation. Fetal opiate
addiction and withdrawal can lead to intrauterine fetal
demise.8 Short-term use of narcotic agents has been
approved. It should be remembered that NSAIDs should
be avoided because these agents block prostaglandin
synthesis and can lead to premature closure of the duc-
tus arteriosus.
Laparoscopic splenectomy has been performed safely
with minimal morbidity.13 It is also being safely per-
formed in nonpregnant patients with ITP.14 Angled
scopes of 30° or 45° facilitate visualization. Positioning in
the right lateral position allows the spleen to fall medial-
ly facilitating dissection. The ultrasonic coagulator, used
commonly in antireflux procedures, is gaining wider use.
It vibrates at 55,000 cycles per second to divide and
coagulate tissues. It can be used on the nonvascular
splenic ligaments as well as the short gastric vessels.
When dividing vessels, it is better to place a short burst
proximally and distally on the vessel before dividing.
This is the method used in our patient with minimal
blood loss. Other options for dividing the vessels include
suture ligation or Ligaclip.13 The larger hilar vessels were
divided with a vascular stapling device. At this point,
bleeding can occur when vessels are partially transected.
After coaxing the spleen into the entrapment sac, a mor-
cellating device or ringed forceps can be used to break
it apart for removal. Laparoscopic splenectomy in non-
gravid patients was successful with only 11% of patients
requiring conversion to an open procedure in a study of
52 procedures.13 This conversion rate decreased with the
increasing experience of clinicians, as noted in other
laparoscopic procedures.
In conclusion, this report suggests that laparoscopic
splenectomy may be safely performed during pregnancy
confirming other recent case reports.15,16 To date, the
risks to the mother and fetus have been shown to be
minimal during laparoscopic cholecystectomy and
appendectomy in small and large collective series up to
20 weeks gestation.11,17 It may be appropriate to extrap-
olate these data to laparoscopic splenectomy. The bene-
fits of laparoscopic procedures in general are well docu-
mented. When applied to pregnant patients, the earlier
return to activity and reduction in narcotic use are addi-
tional benefits that must be weighed against operative
time. Randomized prospective studies are needed before
laparoscopic splenectomy can be routinely offered dur-
ing pregnancy.References:
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